Cargando…

Phase II trial of eribulin mesylate as a first- or second-line treatment for locally advanced or metastatic breast cancer: a multicenter, single-arm trial

BACKGROUND: Eribulin mesylate is currently indicated as a sequential monotherapy to be administered after two chemotherapeutic regimens, including anthracycline and taxane treatments, for treatment of metastatic breast cancer. This open-label, multicenter phase II study was designed to evaluate the...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hayashida, Tetsu, Jinno, Hiromitsu, Mori, Katsuaki, Sato, Hiroki, Matsui, Akira, Sakurai, Takashi, Hattori, Hiroaki, Takayama, Shin, Wada, Masahiro, Takahashi, Maiko, Seki, Hirohito, Seki, Tomoko, Nagayama, Aiko, Matsumoto, Akiko, Kitagawa, Yuko
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2018
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6027765/ https://www.ncbi.nlm.nih.gov/pubmed/29954362 http://dx.doi.org/10.1186/s12885-018-4628-7

Ejemplares similares

Feasibility study on collecting patient‐reported outcomes from breast cancer patients using the LINE‐ePRO system
por: Hayashida, Tetsu, et al.
Publicado: (2022)

A randomized controlled study comparing a vessel sealing system with the conventional technique in axillary lymph node dissection for primary breast cancer
por: Seki, Tomoko, et al.
Publicado: (2016)

Establishment of a deep‐learning system to diagnose BI‐RADS4a or higher using breast ultrasound for clinical application
por: Hayashida, Tetsu, et al.
Publicado: (2022)

Loss of B-cell translocation gene 2 expression in estrogen receptor-positive breast cancer predicts tamoxifen resistance
por: Takahashi, Maiko, et al.
Publicado: (2014)

Cooperation of Cancer Stem Cell Properties and Epithelial-Mesenchymal Transition in the Establishment of Breast Cancer Metastasis
por: Hayashida, Tetsu, et al.
Publicado: (2011)

Eribulin mesylate in the treatment of metastatic breast cancer
por: Jain, Sarika, et al.
Publicado: (2012)

An E2F1-HOXB9 Transcriptional Circuit Is Associated with Breast Cancer Progression
por: Zhussupova, Aisulu, et al.
Publicado: (2014)

Increased frequency of ESR1 mutation in metastatic breast cancer by dosing selective estrogen receptor modulator followed by aromatase inhibitor
por: Takeshima, Kaoru, et al.
Publicado: (2020)

Efficacy and safety of eribulin mesylate in advanced soft tissue sarcomas
por: Noujaim, Jonathan, et al.
Publicado: (2016)

Eribulin mesylate exerts antitumor effects via CD103
por: Oya, Kazumasa, et al.
Publicado: (2023)

Eribulin mesylate in patients with refractory cancers: a Phase I study
por: Mukohara, Toru, et al.
Publicado: (2011)

Pharmacokinetics of eribulin mesylate in cancer patients with normal and impaired renal function
por: Tan, Antoinette R., et al.
Publicado: (2015)

Identification of a Modified HOXB9 mRNA in Breast Cancer
por: Nakashoji, Ayako, et al.
Publicado: (2020)

Eribulin mesylate as a microtubule inhibitor for treatment of patients with metastatic breast cancer
por: Muñoz-Couselo, Eva, et al.
Publicado: (2011)

Eribulin Mesylate Targets Human Telomerase Reverse Transcriptase in Ovarian Cancer Cells
por: Yamaguchi, Satoko, et al.
Publicado: (2014)

Clinical Utility of Eribulin Mesylate in the Treatment of Breast Cancer: A Chinese Perspective
por: Yuan, Peng, et al.
Publicado: (2021)

Eribulin mesylate exerts specific gene expression changes in pericytes and shortens pericyte-driven capillary network in vitro
por: Agoulnik, Sergei I, et al.
Publicado: (2014)

Eribulin mesylate reduces tumor microenvironment abnormality by vascular remodeling in preclinical human breast cancer models
por: Funahashi, Yasuhiro, et al.
Publicado: (2014)

Eribulin Mesylate in Pretreated Breast Cancer Patients: A Multicenter Retrospective Observational Study
por: Gamucci, Teresa, et al.
Publicado: (2014)

Eribulin Mesylate-related Multifocal Demyelinating Neuropathy with Myokymia in a Breast Cancer Patient
por: Tsunogae, Marie, et al.
Publicado: (2021)

Eribulin mesylate induces bone mass loss by promoting osteoclastic bone resorption in mice
por: Ishizaka, Takahiro, et al.
Publicado: (2023)

The relationship between work-related outcomes and symptoms in early breast cancer survivors receiving adjuvant endocrine therapy
por: Nakao, Mayumi, et al.
Publicado: (2022)

Self-rated cognitive functions following chemotherapy in patients with breast cancer: a 6-month prospective study
por: Kitahata, Ryosuke, et al.
Publicado: (2017)

A Case of Brain Metastases from Breast Cancer Treated with Whole-Brain Radiotherapy and Eribulin Mesylate
por: Nieder, Carsten, et al.
Publicado: (2012)

Phase I study of the halichondrin B analogue eribulin mesylate in combination with cisplatin in advanced solid tumors
por: Koczywas, M, et al.
Publicado: (2014)

Eribulin Mesylate Combined with Local Treatment for Brain Metastasis from Breast Cancer: Two Case Reports
por: Byun, Kyung-Do, et al.
Publicado: (2016)

IgG4‐related mastopathy: A case report and literature review
por: Yokoe, Takamichi, et al.
Publicado: (2018)

Neoadjuvant eribulin mesylate following anthracycline and taxane in triple negative breast cancer: Results from the HOPE study
por: Di Cosimo, Serena, et al.
Publicado: (2019)

Investigating the Role of CTCs with Stem/EMT-like Features in Metastatic Breast Cancer Patients Treated with Eribulin Mesylate
por: Papadaki, Maria A., et al.
Publicado: (2022)

Health-related quality of life in patients with locally advanced or metastatic breast cancer treated with eribulin mesylate or capecitabine in an open-label randomized phase 3 trial
por: Cortes, Javier, et al.
Publicado: (2015)

Managing Seroma Formation Post Breast Surgery through Somatostatin Analogs
por: Nagayama, Aiko, et al.
Publicado: (2023)

Skeletal Deformity Associated with SHOX Deficiency
por: Seki, Atsuhito, et al.
Publicado: (2014)

Prospective Analysis of Patients with Metastatic Breast Cancer receiving Eribulin Mesylate as Second or More Lines of Chemotherapy: An Indian Experience
por: Srinivasa, BJ, et al.
Publicado: (2018)

Cost Effectiveness Analysis of Eribulin Mesylate as a Treatment for Metastatic Breast Cancer in Spain: Management in the Later Line of Therapy
por: Tremblay, Gabriel, et al.
Publicado: (2015)

Eribulin mesylate use as third-line therapy in patients with metastatic breast cancer (VESPRY): a prospective, multicentre, observational study
por: Adamo, Vincenzo, et al.
Publicado: (2019)

Bevacizumab terminates homeobox B9-induced tumor proliferation by silencing microenvironmental communication
por: Hoshino, Yoshinori, et al.
Publicado: (2014)

Eribulin mesylate versus ixabepilone in patients with metastatic breast cancer: a randomized Phase II study comparing the incidence of peripheral neuropathy
por: Vahdat, Linda T., et al.
Publicado: (2013)

Health-related quality of life in patients receiving first-line eribulin mesylate with or without trastuzumab for locally recurrent or metastatic breast cancer
por: Schwartzberg, Lee, et al.
Publicado: (2019)

Eribulin Mesylate Improves Cisplatin-Induced Cytotoxicity of Triple-Negative Breast Cancer by Extracellular Signal-Regulated Kinase 1/2 Activation
por: Ko, Hyemi, et al.
Publicado: (2022)

A randomized trial of eribulin monotherapy versus eribulin plus anlotinib in patients with locally recurrent or metastatic breast cancer
por: Liu, B., et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_41oj9vf83iotm4il2rd8r49t2e